122 related articles for article (PubMed ID: 16258472)
21. Dose-intense treatment of mantle cell lymphoma: can durable remission be achieved?
Dreyling M; Hiddemann W
Curr Opin Oncol; 2008 Sep; 20(5):487-94. PubMed ID: 19106649
[TBL] [Abstract][Full Text] [Related]
22. Late-onset neutropenia following viral bone marrow depression after rituximab therapy.
Christopeit M; Haak U; Behre G
Ann Hematol; 2008 Sep; 87(9):761-2. PubMed ID: 18350295
[No Abstract] [Full Text] [Related]
23. Immunotherapy in mantle cell lymphoma: anti-CD20-based therapy and beyond.
Zhou Y; Zhang L; Romaguera J; Delasalle K; Han X; Du X; Kwak L; Yi Q; Wang M
Am J Hematol; 2008 Feb; 83(2):144-9. PubMed ID: 17722077
[TBL] [Abstract][Full Text] [Related]
24. JC papovavirus leukoencephalopathy after first line treatment with CHOP and rituximab.
Rey J; Belmecheri N; Bouayed N; Ivanov V; Coso D; Gastaut JA; Bouabdallah R
Haematologica; 2007 Oct; 92(10):e101. PubMed ID: 18024364
[No Abstract] [Full Text] [Related]
25. Complete response in a patient with colonic mantle cell lymphoma with multiple lymphomatous polyposis treated with combination chemotherapy using anti-CD20 antibody and cladribine.
Watanabe T; Homma N; Ogata N; Saito H; Kanefuji T; Hasegawa K; Soga K; Shibasaki K; Endo T; Ajioka Y
Gut; 2007 Mar; 56(3):449-50. PubMed ID: 17339260
[No Abstract] [Full Text] [Related]
26. Cytomegalovirus-associated meningoradiculoneuritis after treatment of mantle cell lymphoma with a combination of chemotherapy and rituximab.
Vallet S; Tempescul A; Tran A; Legrand-Quillien MC; Narbonne V; Berthou C
Ann Hematol; 2005 Aug; 84(8):545-7. PubMed ID: 15789227
[No Abstract] [Full Text] [Related]
27. High-dose Ara-C and beam with autograft rescue in R-CHOP responsive mantle cell lymphoma patients.
van 't Veer MB; de Jong D; MacKenzie M; Kluin-Nelemans HC; van Oers MH; Zijlstra J; Hagenbeek A; van Putten WL
Br J Haematol; 2009 Feb; 144(4):524-30. PubMed ID: 19036081
[TBL] [Abstract][Full Text] [Related]
28. The role of hematopoietic stem cell transplantation in non-Hodgkin lymphoma.
Villanueva ML; Vose JM
Clin Adv Hematol Oncol; 2006 Jul; 4(7):521-30. PubMed ID: 17147239
[TBL] [Abstract][Full Text] [Related]
29. Rituximab combined with cladribine or with cladribine and cyclophosphamide in heavily pretreated patients with indolent lymphoproliferative disorders and mantle cell lymphoma.
Robak T; Smolewski P; Cebula B; Szmigielska-Kaplon A; Chojnowski K; Blonski JZ
Cancer; 2006 Oct; 107(7):1542-50. PubMed ID: 16948126
[TBL] [Abstract][Full Text] [Related]
30. [Mantle cell lymphoma mimicking chronic lymphocytic leukemia].
Hanamura A; Hayakawa M; Naito K
Rinsho Ketsueki; 2005 Jan; 46(1):13-8. PubMed ID: 16708912
[TBL] [Abstract][Full Text] [Related]
31. Intensive therapies for mantle cell lymphoma: time for a disease-specific approach?
Smith SD; Sweetenham JW
Leuk Lymphoma; 2010 Mar; 51(3):357-9. PubMed ID: 20148757
[No Abstract] [Full Text] [Related]
32. Minimal residual disease detection in mantle cell lymphoma: methods and significance of four-color flow cytometry compared to consensus IGH-polymerase chain reaction at initial staging and for follow-up examinations.
Böttcher S; Ritgen M; Buske S; Gesk S; Klapper W; Hoster E; Hiddemann W; Unterhalt M; Dreyling M; Siebert R; Kneba M; Pott C;
Haematologica; 2008 Apr; 93(4):551-9. PubMed ID: 18379010
[TBL] [Abstract][Full Text] [Related]
33. Review: stem cell transplantation for mantle cell lymphoma: not yet the standard of care.
Sweetenham JW
Clin Adv Hematol Oncol; 2009 May; 7(5):323-4. PubMed ID: 19521321
[No Abstract] [Full Text] [Related]
34. Expression of eukaryotic initiation factor 4E predicts clinical outcome in patients with mantle cell lymphoma treated with hyper-CVAD and rituximab, alternating with rituximab, high-dose methotrexate, and cytarabine.
Inamdar KV; Romaguera JE; Drakos E; Knoblock RJ; Garcia M; Leventaki V; Medeiros LJ; Rassidakis GZ
Cancer; 2009 Oct; 115(20):4727-36. PubMed ID: 19708031
[TBL] [Abstract][Full Text] [Related]
35. Bilateral panocular involvement with mantle-cell lymphoma.
Chappelow AV; Singh AD; Perez VL; Lichtin A; Pohlman B; Macklis R
J Clin Oncol; 2008 Mar; 26(7):1167. PubMed ID: 18309953
[No Abstract] [Full Text] [Related]
36. The hyper-CVAD-rituximab chemotherapy programme followed by high-dose busulfan, melphalan and autologous stem cell transplantation produces excellent event-free survival in patients with previously untreated mantle cell lymphoma.
Ritchie DS; Seymour JF; Grigg AP; Roberts AW; Hoyt R; Thompson S; Szer J; Prince HM
Ann Hematol; 2007 Feb; 86(2):101-5. PubMed ID: 17089127
[TBL] [Abstract][Full Text] [Related]
37. Pre-emptive treatment with rituximab of molecular relapse after autologous stem cell transplantation in mantle cell lymphoma.
Andersen NS; Pedersen LB; Laurell A; Elonen E; Kolstad A; Boesen AM; Pedersen LM; Lauritzsen GF; Ekanger R; Nilsson-Ehle H; Nordström M; Fredén S; Jerkeman M; Eriksson M; Väärt J; Malmer B; Geisler CH
J Clin Oncol; 2009 Sep; 27(26):4365-70. PubMed ID: 19652064
[TBL] [Abstract][Full Text] [Related]
38. Mantle cell lymphoma: new treatments targeted to the biology.
Bertoni F; Ghielmini M; Cavalli F; Cotter FE; Zucca E
Clin Lymphoma; 2002 Sep; 3(2):90-6. PubMed ID: 12435282
[TBL] [Abstract][Full Text] [Related]
39. Proliferation predicts failure-free survival in mantle cell lymphoma patients treated with rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with rituximab plus high-dose methotrexate and cytarabine.
Garcia M; Romaguera JE; Inamdar KV; Rassidakis GZ; Medeiros LJ
Cancer; 2009 Mar; 115(5):1041-8. PubMed ID: 19170236
[TBL] [Abstract][Full Text] [Related]
40. Fludarabine, cyclophosphamide, and rituximab for the treatment of patients with chronic lymphocytic leukemia or indolent non-Hodgkin lymphoma.
Tam CS; Wolf M; Prince HM; Januszewicz EH; Westerman D; Lin KI; Carney D; Seymour JF
Cancer; 2006 Jun; 106(11):2412-20. PubMed ID: 16649223
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
